32
Participants
Start Date
April 30, 2022
Primary Completion Date
April 30, 2023
Study Completion Date
December 30, 2025
Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab
"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
"Induction therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip)+gemcitabine (1,000 mg/m2), every 3 weeks for 3 cycles before radiotherapy.~Concurrent therapy:~Toripalimab (240mg iv drip)+Bevacizumab (7.5mg/kg iv drip), every 3 weeks for 2 cycles during radiotherapy.~Adjuvant therapy:~Toripalimab (240mg iv drip), every 3 weeks for 1 year after radiotherapy.~Radiation:~Intensity-modulated radiotherapy."
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou
The First Affiliated Hospital of Nanchang University
OTHER
Sun Yat-sen University
OTHER